Brief: Vyne Therapeutics Announces First Subjects Dosed In Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, For The Treatment Of Vitiligo

YARROW BIOSCIENCE

17/11/2022 13:28

Nov 17 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN PHASE
1A/B
CLINICAL TRIAL EVALUATING PAN-BET INHIBITOR, VYN201, FOR THE
TREATMENT OF VITILIGO
    * VYNE THERAPEUTICS - LOOK FORWARD TO TOPLINE DATA FOR BOTH
PHASE
1A AND PHASE 1B PORTIONS OF STUDY, EXPECTED IN FIRST HALF OF
2023

Source text for Eikon:  ID:nGNX510hsw 
Further company coverage:  VYNE.O